Vol. 10, Issue 4 (2021)

Background and objective: In the management of type 2 diabetes mellitus, repaglinide and voglibose were given to newly diagnosed patients of various ages and genders who had postprandial hyperglycemia. The researchers in this trial set out to see how far repaglinide (1 mg) and voglibose (3 mg) could take individuals with newly diagnosed type II diabetes mellitus in terms of preventing postprandial hyperglycemia.

Materials and Methods: A cross-sectional observational study was this one. Researchers from Sukhsagar Medical College in Jabalpur, Madhya Pradesh, India, conducted the study. The research period for this project was from March 2020 to February 2021. One hundred patients were enrolled in the trial and split evenly between two groups: group A and group B. The A group received 1 milligram of Repaglinide, while the B group received 3 milligrams of voglibose. Fasting and postprandial blood sugar levels were measured using oxidase methods in the auto-analyzer, while hemoglobin A1c levels were determined using the capillary electrophoresis method.

Results: Before and three months after starting medicine, the hbA1c levels in groups A and B were checked. Also, there was a significant p-value between the average readings of the two groups that were given different drugs. After three months of therapy, the mean FBS levels for both groups were very different from what they were before. The patients in group A had the fewest side effects, and their BMI was higher than that of patients in group B.

Conclusions: Even though both drugs worked about as well at lowering post-meal hyperglycemia, Repaglinide was better because it had fewer side effects.